View in EDS HTML Full Text PDF Full Text

Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis

Saved in:
Bibliographic Details
Title: Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis
Authors: Blauvelt, Andrew1 (AUTHOR), Kircik, Leon2,3 (AUTHOR), Schlesinger, Todd4,5 (AUTHOR), Pierce, Evangeline6 (AUTHOR) evangeline.pierce@lilly.com, Burge, Russel6,7 (AUTHOR), Behling, Michael8 (AUTHOR), Atwater, Amber Reck6 (AUTHOR), ElMaraghy, Hany6 (AUTHOR), Armstrong, April9 (AUTHOR)
Source: Journal of Dermatological Treatment. Dec2025, Vol. 36 Issue 1, p1-9. 9p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:09546634
DOI:10.1080/09546634.2024.2442720